GLPwatch

High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.

Child Obes · 2025

Last updated 2026-05-28

In a study of 125 pubertal adolescents with obesity taking the weight-loss drug liraglutide, the change in BMI z-score (a measure of weight status) varied depending on which growth reference was used. Using the World Health Organization (WHO) reference, the BMI z-score dropped by 0.26, while using the CDC 2000 reference, it dropped by 0.13. For those with very high baseline BMI z-scores, the difference was even larger, ranging from 0.05 (CDC 2000) to 0.19 (WHO).

AI summary of the abstract below.

JournalChild Obes, 2025
Citations1
Molecules
Conditions studied Obesity

Abstract

The BMI z-score is a standardized measure of weight status and weight change in children and adolescents. BMI z-scores from various growth references are often considered comparable, and differences among them are underappreciated. This study reanalyzed data from a weight management clinical study of liraglutide in pubertal adolescents with obesity using growth references from CDC 2000, CDC Extended, World Health Organization (WHO), and International Obesity Task Force. BMI z-score treatment differences varied 2-fold from -0.13 (CDC 2000) to -0.26 (WHO) overall and varied almost 4-fold from -0.05 (CDC 2000) to -0.19 (WHO) among adolescents with high baseline BMI z-score. Depending upon the growth reference used, BMI z-score endpoints can produce highly variable treatment estimates and alter interpretations of clinical meaningfulness. BMI z-scores cited without the associated growth reference cannot be accurately interpreted.

Verbatim abstract via PubMed 38995874 ↗